Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest added to existing positions in Netflix, Oklo, and Intuitive Surgical on Wednesday, despite all three stocks being down over the past year. Netflix’s targeted 11.5% revenue growth for the current quarter would be its slowest in more than three years, while Oklo has fallen 86% from its October peak and is not expected to generate more than $10 million in revenue next year. Intuitive Surgical is down 7% over the past year, with analysts expecting revenue growth to slow to 13% in the new quarter; the article notes its continued earnings beats and the switching costs of its da Vinci platform.

Analysis

Treat Ark’s disclosed buying as a sentiment signal, not evidence of improving fundamentals: the trades are backward-looking and may be too small to alter supply-demand. Near term, NFLX faces asymmetric execution risk: if subscriber monetization and advertising fail to offset slower growth, estimate cuts can overwhelm an apparently cheaper earnings multiple. The contrarian case is that a large global audience gives Netflix room to improve ad yield, but that requires proof in reported ad revenue and engagement—not just a larger ad-tier footprint.

OKLO is fundamentally different: it is long-duration technology and permitting optionality, not a near-term earnings compounder. Cash reduces near-term financing pressure but does not remove project execution, licensing, or eventual dilution risk; AI power demand can benefit the whole sector without guaranteeing Oklo captures contracts. ISRG has the clearest installed-base and switching-cost support, but competitors such as Medtronic and Johnson & Johnson can pressure future placements, pricing, and procedure economics. Watch utilization and system placements, not only earnings beats.

Over days, positioning-driven volatility may dominate. Over 1–3 months, guidance revisions and operating metrics matter more than manager disclosures. Over 6–18 months, ISRG’s competitive retention and OKLO’s licensing/project milestones are the key thesis tests. The contrarian opportunity is selective: ISRG may offer the most defensible recovery setup; OKLO’s drawdown alone is not a valuation floor.

Key Decisions for Investors

• Do not mirror Ark’s buys mechanically. For NFLX, wait for the next report or guidance update to show stabilization in revenue expectations and measurable ad monetization before adding; a further downward revision or weakening engagement falsifies the recovery case.
• ISRG: consider a staged long on evidence that procedure growth and system placements remain resilient; keep exposure below a normal core position until competitive displacement is measurable. Reassess if utilization or placements weaken across successive updates, or competitors win meaningful share.
• OKLO: keep as a high-volatility watchlist position rather than a fundamentals-backed long until licensing progress, project milestones, and credible customer commitments are independently verifiable. Regulatory delay, rising project costs, or financing needs would invalidate the cash-buffer argument.
• Avoid treating the three names as one dip-buying basket. If expressing a relative view, favor ISRG over OKLO on a risk-adjusted basis, with defined downside limits; the thesis is stronger operating visibility, not a near-term catalyst guarantee.